Purespring on nephrology & gene therapy in kidney disease
Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.
Newsletters and Deep Dive digital magazine
Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.
The patent cliff isn't the problem. It's the symptom.
Biosimilars can help support broader patient access while contributing to the long-term sustainability of healthcare systems.
When hospitals in the United States began delaying elective procedures in 2024 over a shortage of intravenous saline solutions, it exposed a structural vulnerability that rarely makes headl
The latest Board moves reflect a focus on experience in commercialisation, corporate governance, and therapeutic development.
Editor's Picks
Newsletters and Deep Dive
digital magazine